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OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
aquatic therapy is effective in improving motor activity in patients with Parkinson’s disease. 
 
STUDY DESIGN: A systematic review of three English language primary studies, one of which 
published in 2011 and two in 2017. 
 
DATA SOURCES: Three randomized control trials (RCT); two single blind and one controlled, 
open-pilot trial published in peer-reviewed journals analyzing if aquatic therapy is effective in 
improving motor activity in patients with Parkinson’s disease. Articles were found on PubMed. 
 
OUTCOMES MEASURED: The outcome measured was motor activity using the Unified 
Parkinson’s Disease Rating Scale (UPDRS) section III. 
 
RESULTS: All three studies found that aquatic therapy significantly improved motor activity 
when compared to traditional land-based therapy in Parkinson’s diseased patients. Carroll et al. 
study showed a mean change from baseline for the aquatic therapy group in motor activity at 6 
weeks and no mean change from baseline the control group.  When comparing the two groups, 
there was a clinically significant change, p=0.01(Carroll LM, Volpe D, Morris ME, Saunders J, 
Clifford AM. Arch Phys Med Rehabil. 2017;98(4):631-638. doi: S00039993(17)30002-3 [pii]). 
Vivas et al. study did a follow-up ANOVA that showed participants in the water-group, from 
pretest to posttest, changed significantly in the UPDRS, motor aspect, compared to participants 
in the land-based group. Between the groups there was a statistically significant difference in the 
water-group, with a p-value of 0.001 (Vivas J, Arias P, Cudeiro J. Arch Phys Med Rehabil. 
2011;92(8):1202-1210. doi: 10.1016/j.apmr.2011.03.017 [doi]).  Perez de la Cruz et al. study 
found that the experimental group had significant differences post-treatment in improved motor 
activity, with a p value P<0.001, compared to the control group where no improvement was seen 
(Perez de la Cruz S. Eur J Phys Rehabil Med. 2017;53(6):825-832. doi: 10.23736/S1973-
9087.17.04647-0 [doi]). 
	
CONCLUSSIONS: The evidence presented in this review shows that aquatic therapy does 
improve motor activity in individuals with Parkinson’s disease.  Significant results were found in 
each article, however, due to limitations, including small sample sizes, further research should be 
done to confirm these findings. 
 










Parkinson’s disease (PD) is a neurodegenerative disorder that affects different regions of 
the brain, most commonly the area called the substantia nigra.  This area of the brain specifically 
controls balance and movement.  Patients with Parkinson’s disease lose cells in the substantia 
nigra and are seen to have dopamine concentrations that are markedly decreased.1  The incidence 
of Parkinson’s disease increases with age. It affects more than one million people in North 
America and over four million people worldwide.2 There are approximately 60,000 new cases 
per year and 13 per 100,000 people affected in the United States.1,2  With such a high prevalence, 
it is crucial to research therapies that will help slow the progression of motor symptoms in these 
patients.  
 According the American Journal of Managed Care (AJMC), as of June 2019, Parkinson’s 
disease accounted for an estimated economic burden of $25.4 billion from medical costs, $26.5 
billion from missed work, lost wages, forced early retirement and caregiver time.3 With regards 
to healthcare visits, in 2015, approximately 200,000 patients with Parkinson’s disease were 
hospitalized, 37,000 were readmitted to the hospital, 9,700,000 patients attended an outpatient 
visit, 34,000 were put on hospice, 113,000 lived in skilled nursing facilities and 466,000 made 
visits to the emergency room.4 
Currently, the exact cause of Parkinson’s disease is unknown, however, several factors 
play a role in the etiology of the disease. Some factors include genetics, while other factors 
include environmental triggers.1  Familial cases of Parkinson’s disease can be caused by a 
mutation in certain genes codes, but these cases are unpredictable; being that some patients with 
these mutations may have no known family history.2  Cardinal symptoms of Parkinson’s disease 
include tremors, bradykinesia, rigidity, impaired posture and balance, and loss of autonomic 
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movements.1,2  Carbidopa-levodopa (Sinemet) is currently the most effective medication to treat 
the symptoms in Parkinson’s disease.5 Dopamine agonists, monoamine oxidase B (MAO-B) 
inhibitors, catechol O-methyltransferase (COMT), and anticholinergics are medications that can 
be used as an adjuvant therapy with carbidopa-levodopa to improve symptoms.  Surgical deep 
brain stimulation is indicated for patients who are resistant to medications.5 Physical therapy and 
occupational therapy also play a role in symptomatic management of Parkinson’s disease. These 
therapies are important to improve motor skills and gait disturbances along with activities of 
daily living.2  Currently, there is no cure for Parkinson’s disease, however, the pharmalogic, 
surgical and non-pharmalogic treatments mentioned above are used to manage symptoms of the 
disease. As of now, aquatic therapy is not used routinely for the management of Parkinson’s 
disease. Aquatic therapy can help patients with the disease move more easily while reducing the 
fear of falling.6  
This paper evaluates three randomized control trials (RCTs) comparing the efficacy of 
aquatic therapy for improving motor activity in adult patients with Parkinson’s disease compared 
to traditional land therapy. Physical exercise has the potential to be helpful for Parkinson patients 
on a motor level, including things like gait, balance, strength and posture.5  Combining physical 
exercise and water therapy makes a safer environment for patients with Parkinson’s disease and 
also makes therapy more beneficial. The water provides increased resistance for these patients as 
they progress through their therapy.6  Along with that, water therapy allows the therapist to 
control the temperature and having warmer temperatures provide an additional therapeutic effect 
that can help improve rigidity symptoms in Parkinson patients; and allow them to complete a 
more effective training session.5 
 




The objective of this selective EBM review is to determine whether or not “Is aquatic 
therapy effective in improving motor activity in patients with Parkinson’s disease?”  
METHODS 
Key words used to search the literature included hydrotherapy and Parkinson’s disease. 
All articles were published in the English language and in peer-reviewed journals.  The articles 
were discovered via PubMed and selected based on relevance to my clinical question and if they 
included patient oriented outcomes (POEMS). Inclusion criteria for this study necessitated that 
these studies were RCTs, published in English, primary articles, published on or after 2011.  
Exclusion criteria included systemic reviews and articles published before 2011. Summary of 
statistics used included mean change from baseline and P-values.    
The studies utilized in this review include three randomized control trials; two single 
blind and one controlled, open-pilot trial. The population consists of adults with Parkinson’s 
disease Hoehn and Yarhr Scale 1-3.  The intervention used was water therapy, and the control 
group received traditional land therapy. The outcomes measured in all three studies were the 
improvement of overall motor activity based on the patient’s Unified Parkinson’s Disease Rating 
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Table 1- Demographics & Characteristics of Included Studies 
Study Type # Pts Age 
(yrs) 












Diagnosis of PD 
Hoen and Yahr 
stages 1-3, stable 
medication status 
over last 3 mo., and 
be able to walk 
10m 3x w/o 
assistance 
Contraindications 
to aquatic therapy, 
including CVD or 
pulmonary 
conditions, 
previous history of 
deep brain 
stimulation, or any 
musculoskeletal 
condition that 
affects their ability 























of PD Hoen and 
Yahr stages 2-3 in 
off-medication 
phase and lack of 
dementia 


















30 > 40 
years 
old 
Diagnosis of PD 
Hoen and Yahr 
stages 1-3 in off-
medication phase, 




previous 4 weeks, 
score greater or 





and accept study 
norms 
Individuals who did 
not comply with 
the indication 
criteria and the 
presence of 
articular and/or 
muscular lesions in 
the lower limbs 
affecting 
independent gait 








The outcomes measured in the trials were based on POEMs that assessed the efficacy of 
aquatic therapy and clinical improvement of motor activity in Parkinson patients.  Motor activity 
was measured using section III, the motor aspect, of the Unified Parkinson’s Disease Rating 
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Scale.  Section III measurements included speech, facial expression, tremors at rest, 
action/postural tremors of hands, rigidity, finger taps, hand movements, rapid alternating 
movement, leg agility, arising from a chair, posture, gait, posture stability, body bradykinesia 
and hypokinesia.6,7,8 The provider completes this scale by observing the patient during activity 
and giving the patient a certain number of points based on their performance.9 The lower the 
score the better; scores range from 0 to 4 with 0 being equivalent to normal.9 
RESULTS 
Carroll et al. studied 21 adults aged 65 and older who were randomized and allocated into 
2 groups, aquatic therapy and usual care group (11 intervention group, 10 in usual care group). 
These patients were recruited from Ireland and approved from the Irish Health Service 
Executive.  The diagnosis of Parkinson’s disease for these patients was based on the UK British 
Bank Criteria and confirmed by a neurologist, Hoehn and Yahr stages 1 through 3 with stable 
medication status over the past 3 months.6  These participants were required to be able to walk 
10 meters 3 times without assistance.  Participants were excluded if they had contraindications, 
like cardiovascular or pulmonary conditions, to aquatic therapy, any previous history of deep 
brain stimulation, or any musculoskeletal conditions that affected their ability to exercise.6  
The study conducted by Carroll et al. was a single-blind RCT; the participants were 
blinded to the group allocation and the randomization was carried out using opaque envelopes to 
conceal the allocation by a third party. For UPDRS part III, intention to treat analysis using last 
observation was used.6 The intervention addressed in this study was aquatic exercise therapy 
including 45-minute session 2 times a week for 6 weeks in a local hydrotherapy pool that was 12 
meters long and 6 meters wide with a depth varying from 0.6 to 1.30 meters; the water was set at 
32 degrees Celsius.6  The comparison group received usual care exercise on land with 
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medications. There was a mean change from baseline for the aquatic therapy group using the 
UPDRS section III at 6 weeks with a mean change from baseline being 4.5 points, while the 
mean change from baseline for the usual care group was 0.6  Therefore, when comparing the two 
groups, there was a clinically significant change (p=0.01).6  
Table 2. Outcome variables at T1 (baseline) and T2 (after therapy) and between-group 
differences6 
 Aquatic therapy group 
(n=10) 
Usual care group (n=8) Intervention verse 
usual care group  













NOTES: values are median (interquartile range) or as otherwise indicated. 
*Statistically significant 
Vivas et al. studied 12 adults aged 55 and older (8 men and 4 women) who were 
diagnosed with Parkinson’s disease from the Parkinson’s disease Association of Ferrol, Galicia. 
They were evaluated for baseline (pretest) then randomly allocated to either a land-based therapy 
(active control group) or a water-based therapy (experimental group). Participants were included 
if they were able to follow a stable medication schedule, have been diagnosed with Parkinson’s 
stages 2 or 3 according to Hoehn and Yahr and were not diagnosed with dementia. Participants 
were excluded if they could not walk independently or had to undergo surgery for their disease.7 
 The study conducted by Vivas et al. was a randomized controlled, open-label pilot trial 
where a single physiotherapist performed the sessions with each participant individually for all 
sessions.  The intervention addressed in this study was aquatic therapy including 45-minute 
sessions twice a week for 4 weeks, followed by a retest after the intervention (posttest), and a 
follow-up assessment after 17 days (posttest-2).  Evaluations for each participant were conducted 
with 12-hours of withholding medication.  Aquatic intervention was in a city spa with the pool 
measuring 3.55 meters wide, 7.75 meters long, and 1.30 meters deep with a temperature no less 
than 32 degrees Celsius.7 Before starting the intervention, the groups were similar in variables 
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analyzed. A follow-up ANOVA was performed and showed that participants in the water-group, 
from pretest to posttest, changed significantly in the UPDRS scores compared to participants in 
the land-based group that did not change significantly. In this study a p value of 0.05 was 
required to establish significance.  Between the groups there was a statistically significant 
difference in the water-group, with a p-value of 0.001 as seen in table 3.7 
Table 3. Effects of the Therapy; pretest, posttest, posttest-2 UPDRS part III.7 
UPDRS score Pretest Posttest Posttest-2 Interaction 
evaluation x 
group (E x G 
Follow-up 
ANOVA (if 
significant E x 
G) Factor 
Evaluation 




Land 36.33+/-14.71 32.67+/-11.18 34.83+/-8.18  F2,10-.965, 
p=.414 
NOTE: values are mean +/- SD or as otherwise indicated. Table represents the effect of Factor 
Evaluation along the whole protocol. In case of significant interaction (ExG), which means the effect is 
different for both groups, a follow-up ANOVA was performed. *Statistically significant. 
 
Perez de la Cruz et al. studied 30 patients over the age of 40 with 15 randomly assigned 
to the aquatic sessions (intervention group) and 15 randomly assigned to the dry land therapy 
(control group). These patients were diagnosed with Parkinson’s disease from two Parkinson’s 
associations in Spain.8 Inclusion criteria for this study included individuals diagnosed with 
Parkinson’s disease stages 1 to 3 based on Hoen and Yahr Scale while not on medication, 
receiving dopaminergic therapy over the previous four weeks and who had a score of 24 or more 
on a Mini-Mental State Examination Scale.8 Patients were excluded if they did not comply with 
the inclusion criteria and if there was the presence of articular and/or muscular lesion in the 
lower extremities that would alter their independent gait.8 
 The study conducted by Perez de la Cruz et al. was a single blind RCT where all patients 
received an initial 30 to 45 minute assessment on land for a baseline measurement.  Once 
randomized into the two groups, the control group received 20 twice-weekly sessions over 10 
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weeks; each session was 45 minutes. The intervention group received 20 twice-weekly sessions 
during the same period as the control group; these were also 45-minute sessions.  The aquatic 
therapy took place in a pool measuring 25x6 meters and a depth of 110 to 145 centimeters with a 
water temperature of 30 degrees Celsius.8  For this study, a power calculation analyses (G-
power) indicated a sample size of 15 was required for each group in order to detect a decrease in 
UPDRS motor score. The groups were required to detect an effect size of Cohen’s d=0.56 for a 
reduction in UPDRS score (5 point decrease) in the aquatic group when compared to the land 
therapy group (power=0.8, alpha=0.05, correlation with covariate=0.05).8  Patients from each 
group were analyzed at baseline, post-treatment and one-month follow-up. For motor activity 
using the UPDRS scale, Perez de la Cruz et al, wrote in his article that “there were significant 
differences in almost all sections under study, with exception of section four”.8 This does not 
correlate with the date found on table 4. The aquatic therapy group’s mean measurement was 
15.33 pre-test and remained 15.33 post-test 1 and 2. However, the treatment*time did have an 
effect, with a F=23.1 and a P-value < 0.001. So, that F value and P value both correlate with 
Cruz’s narrative but the mean measurement and standard deviation data does not.8 
Table 4. Results for the Unified Scale for the Assessment of Parkinson’s disease (UPDRS).8 
 Measure Mean (SD) Intra-subject effects** 
Variable Pre  Post  Post-2 Time 
F(d.f); P value (eta2) 
Treatment*time 
F(d.f); P value (eta2) 




Dry  15.13(7.1) 15.07(7.1) 15.07 (7.1) NOTES: d.f.: degrees of freedom. Eta2: partial 
eta squared (Effect size).  Aquatic  15.33(7.5) 15.33(7.5) 15.33(7.5) 
Total 15.23(7.3) 15.20(7.3) 15.20(7.3) 
 
DISCUSSION 
 Carroll et al. and Vivas J et al. both elicited statistically significant improvements for 
Parkinson patients in motor activity, including things like balance, mobility, bradykinesia and the 
symptoms measured on the motor aspect section of the Unified Parkinson’s Disease Rating 
Argudo- Aquatic Therapy and Parkinson’s Disease 10	
	
	
Scale. Perez de la Cruz et al. also showed a statistically significant improvement in motor 
activity as stated in the author’s narrative. However, I believe that table 4, representing the mean 
and standard deviation for UPDRS 3 was incorrectly published and does not correlate with the 
narrative in the article. The aquatic group had identical means and standard deviations for all 
three measurements, but the treatment time on the right side of table 4 shows clinical 
significance to match the narrative. Therefore, I believe the narrative and treatment time are 
correct and with that, they answer my clinical question. Through my research, I was not able to 
find any errata published to correct this error. 
 A limitation in Carroll et al. was that the sample size calculation was based on an 
estimate of the change reported for the UPDRS score, since no other studies at that time tested 
for the same thing. This study also looked at a rather small sample size, which could have 
possibly affected the ability to detect a significant change.6  Along with that, the patients tested 
in this study fell under a diagnosis of early to middle stages of Parkinson’s disease excluding 
evidence for more advanced stages, leaving the effects for aquatic therapy on these patients 
unknown.6  A limitation in Vivas J et al. was that the patients in the control group at baseline 
were diagnosed with Parkinson’s disease much longer than the patients in the experimental 
group. Also, the outcomes for the UPDRS in this study combined all sections into one.7   A 
limitation in Perez de la Cruz et al. was the small sample size and the short follow-up period, 
which in turn could have falsely magnified the results in the study.  
 With regards to my research, I was only able to find these three articles that specifically 
used UPDRS scale to measure motor ability.  Other articles had to be excluded due to my 
decision to only use English language articles and articles published on or after 2011.  Two of 
my three articles used the entire UPDRS scale, including section 3 but not limited to it, so the 
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scores took all aspects into consideration. While on the other hand, one of the articles used 
specifically section 3 of the UPDRS scale. Another limitation in my research that would 
potentially make the statistical findings not really significant after all is considering the clinical 
importance difference of the UPDRS scores. According to Shulman et al. a clinically important 
difference in the motor aspect of UPDRS is a decrease of 2.5 points for a minimal, 5.2 points for 
a moderate and 10.8 points for a large difference.9  
CONCLUSSION 
   The intervention of aquatic therapy when compared to a land-based therapy did show 
statistically significant improvements in motor activity in individuals with Parkinson’s disease.  
Aquatic therapy is an efficient, easy, enjoyable and safe intervention for patients diagnosed with 
varying stages of Parkinson’s disease (Hoehn and Yahr Scale 1-3), and can be considered as a 
treatment protocol but should not be a standard of care since it has not proven to have 
exponentially greater outcomes than land-based therapy. Pools are easily accessible and are well 
affordable providing a cost-effective option for therapy. Aquatic therapy can be considered by 
health professionals as an adjuvant therapy to medication, physical therapy (land-based) and 
occupational therapy. However, studies should be carried out with greater sample sizes for 
longer periods to confirm these findings and ensure the longevity of the benefits. Researchers 
should also take into consideration if patient’s medication is in an “ON” or “OFF” state. Along 
with that, the treatment effect needs to be compared to clinically important differences of 
UPDRS scores in order to tell whether the improvement of scores were really significant. Lastly, 
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